Goldman Sachs Group, Inc. (GS.US) plans to merge its investment banking operations in the Asia-Pacific region to create a unified department.
Goldman Sachs plans to merge its investment banking operations in the Asia-Pacific region in order to provide clients with more integrated advisory services and capital markets execution services.
An internal memo shows that Goldman Sachs plans to merge its teams in Japan, Australia, and New Zealand, as well as other Asian regions excluding Japan, to create a unified regional investment banking business. The consolidated Asia Pacific investment banking department will be led by Iain Drayton, a spokesperson confirmed the authenticity of the memo.
"This structure will enable more comprehensive client engagement, more efficient mobilization of global and regional expertise, and provide more career development opportunities for our employees," the memo stated.
Iain Drayton currently heads Goldman Sachs' Asia (excluding Japan) investment banking business. In his new role, Iain Drayton will work closely with Yoshihiko Yano and Shogo Matsuzawa, Co-Heads of Investment Banking in Japan, as well as Nick Sims and Zac Fletcher, Co-Heads of Corporate Advisory in Australia and New Zealand.
According to data compiled by Dealogic, Goldman Sachs topped the Asia Pacific equity capital markets league table this year with 32 deals totaling $9.8 billion, capturing a 12% market share. Competitors J.P. Morgan and Morgan Stanley closely followed.
Related Articles

BIOSTAR PHARM-B(02563): Zhu Pai resigns as non-executive director

GLOBAL BIO-CHEM (00809) and Hefei Hemei will establish and collaborate to operate a synthetic biology pilot platform at the Xinglong Mountain production base.

Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH) passed the drug GMP compliance inspection.
BIOSTAR PHARM-B(02563): Zhu Pai resigns as non-executive director

GLOBAL BIO-CHEM (00809) and Hefei Hemei will establish and collaborate to operate a synthetic biology pilot platform at the Xinglong Mountain production base.

Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH) passed the drug GMP compliance inspection.

RECOMMEND

Xiaomi Unveils 3nm Chip and YU7 SUV at 15th Anniversary Event
23/05/2025

BYD Surpasses Tesla in European EV Sales for the First Time in April with 169% Surge; Tesla Sees 45% Q1 Decline, Musk Reaffirms CEO Role for Five More Years
23/05/2025

U.S. FTC Officially Withdraws Case Against Microsoft’s $69 Billion Acquisition of Activision Blizzard
23/05/2025